Utah Medical Products (NASDAQ:UTMD) Share Price Passes Above 200-Day Moving Average – Time to Sell?

Utah Medical Products, Inc. (NASDAQ:UTMD) shares crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $59.23 and traded as high as $64.24. Utah Medical Products shares last traded at $63.73, with a volume of 12,256 shares.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (d+)” rating on shares of Utah Medical Products in a research report on Wednesday, January 21st. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has a consensus rating of “Sell”.

Utah Medical Products Trading Up 0.6%

The company has a market capitalization of $205.12 million, a PE ratio of 18.42 and a beta of 0.34. The company has a fifty day simple moving average of $59.45 and a 200-day simple moving average of $59.27.

Utah Medical Products (NASDAQ:UTMD) last announced its quarterly earnings results on Thursday, January 29th. The medical instruments supplier reported $0.80 earnings per share for the quarter. Utah Medical Products had a net margin of 29.30% and a return on equity of 9.60%. The firm had revenue of $9.04 million for the quarter.

Utah Medical Products Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, April 3rd. Stockholders of record on Tuesday, March 17th will be issued a dividend of $0.31 per share. The ex-dividend date is Tuesday, March 17th. This represents a $1.24 dividend on an annualized basis and a dividend yield of 1.9%. Utah Medical Products’s dividend payout ratio (DPR) is currently 35.63%.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. O Shaughnessy Asset Management LLC raised its position in Utah Medical Products by 2.3% in the fourth quarter. O Shaughnessy Asset Management LLC now owns 14,903 shares of the medical instruments supplier’s stock valued at $834,000 after purchasing an additional 337 shares during the period. First Horizon Advisors Inc. increased its position in shares of Utah Medical Products by 159.7% during the 2nd quarter. First Horizon Advisors Inc. now owns 587 shares of the medical instruments supplier’s stock worth $33,000 after purchasing an additional 361 shares during the last quarter. Everett Harris & Co. CA raised its holdings in Utah Medical Products by 2.1% in the 2nd quarter. Everett Harris & Co. CA now owns 17,478 shares of the medical instruments supplier’s stock valued at $995,000 after buying an additional 362 shares during the period. Comerica Bank lifted its position in Utah Medical Products by 435.6% in the third quarter. Comerica Bank now owns 541 shares of the medical instruments supplier’s stock valued at $34,000 after buying an additional 440 shares during the last quarter. Finally, Cardinal Capital Management lifted its position in Utah Medical Products by 1.9% in the fourth quarter. Cardinal Capital Management now owns 24,836 shares of the medical instruments supplier’s stock valued at $1,394,000 after buying an additional 459 shares during the last quarter. 69.60% of the stock is currently owned by hedge funds and other institutional investors.

Utah Medical Products Company Profile

Utah Medical Products, Inc (NASDAQ: UTMD), headquartered in Midvale, Utah, is a designer, manufacturer and marketer of single‐use medical devices focusing principally on respiratory therapy and patient monitoring applications. Since its founding in the late 1970s, the company has built a reputation for innovation in airway management and non‐invasive monitoring products used in acute and long‐term care settings.

The company’s core product portfolio includes tracheostomy tubes and related accessories, endotracheal tube holders, disposable catheters and sensors for measuring end‐tidal carbon dioxide (CO₂).